ERBB2 and breast carcinoma: With the availability of broad range anti-HER-2 drugs, such as trastuzumab, lapatinib, pertuzumab, pyrotinib, and trastuzumab emtansine (T-DM1), the prognosis among patients with HER-2+ early and advanced breast cancer has significantly improved (4).